PO.CL01.12 · 临床研究

Spatial 3D and multi-omics mapping of diffuse gastric cancer evolution from preinvasive to invasive lesions in CDH1 mutation carriers

海报缩略图:Spatial 3D and multi-omics mapping of diffuse gastric cancer evolution from preinvasive to invasive lesions in CDH1 mutation carriers
编号 1201 展板 2 时间 4/19 02:00–05:00 区域 Section 47 主讲 Yunhe Liu, PhD
分会场 Spatial Proteomics and Transcriptomics 1
查看完整资料 下载 PDF 登录后可访问当前开放资料 AACR 官方页面 ↗

作者与单位

Yunhe Liu1, Idania Carolina Lubo Julio2, Wei Lu2, Alejandra G. Serrano2, Jean R. Clemenceau3, Amber Famiglietti4, Karen Colbert5, Yibo Dai1, Yang Liu1, Jun Wang1, Jeremy L. Davis6, Mingyao Li7, Paul F. Mansfield8, Tae Hyun Hwang3, Luisa M. Solis-Soto9, Linghua Wang1

1Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX,2Department of Translational and Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX,3Department of Surgery, Vanderbilt University Medical Center, Nashville, TN,4National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD,5Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX,6BioChemistry&Molecular Biology, University of Maryland School of Medicine, Baltimore, MD,7University of Pennsylvania, Philadelphia, PA,8Vice President, Acute Care Services, UT MD Anderson Cancer Ctr., Houston, TX,9Department of Translational Molecular Pathology, the university of MD Anderson cancer center, Houston, TX

摘要 Abstract

Background: Hereditary diffuse-type gastric cancer (DGC) lacks a defined precursor sequence. Germline CDH1 loss-of-function mutations confer a high lifetime risk, and prophylactic gastrectomies in asymptomatic carriers frequently reveal numerous occult intramucosal signet-ring cell (SRC) foci that can remain indolent for years. The biological mechanisms underlying the progression from these indolent SRC foci to invasive DGC remain largely unknown. Methods: We profiled primary DGCs from 26 patients, sampling the full histologic continuum from SRC foci to invasive lesions and overtly invasive fronts. Whole-slide sections were pathologist-annotated for tumor subtype and key microenvironmental features. Serial sections were assayed with complementary spatial multi-omics platforms: GeoMx DSP, Visium, Xenium Prime 5K with post hoc Codex (IO60), and CosMx (WTX). Selected specimens also underwent high-plex spatial multi-omics sequencing (transcriptome/protein/TCR/BCR) using Singular G4X, as well as 3D modeling with both Singular G4X and holotomography (HT-X1). Cross-platform datasets were co-registered to common coordinates; cell segmentation, phenotype annotation, and neighborhood/niche mapping quantified transcriptomic dynamics and tumor-microenvironment interactions across regions spanning preinvasive to invasive lesions. Integration of Singular G4X and Label-free holotomography provided 3D context. Results: Spatial transcriptomic profiling revealed invasion-associated transcriptional programs along the SRC-to-invasive continuum. The meta-programs (MPs) associated with discrete stages of progression were defined. Histology-integrated analyses highlighted invasion-depth-dependent shifts in cell-cycle, EMT, and stress-metabolism pathways, and trajectory/differentiation analyses supported a continuous invasion axis. Copy-number inference indicated two evolution trajectories, linear and branched. Single-cell-resolution spatial multi-omics refined tumor cell-state signatures and their spatial neighborhoods, revealing lymphocyte-dominant microenvironmental states at early lesions and stromal/myeloid remodeling with deeper invasion, corroborated by multiplex proteomics (IO60). Cross-section registration with label-free 3D holotomography generated volumetric reconstructions mapping coherent clonal sectors and concordant TME remodeling along the invasion axis. Conclusions: We present a spatial multi-omic atlas of DGC progression. The work delineates subtype- and region-specific gene programs, clonal architectures, and TME remodeling at high spatial and molecular resolution, modeling disease progression in 3D. Our findings identify candidate biomarkers of progression, risk stratification, and potential therapeutic interception of SRC tumorigenesis in CDH1 mutation carriers.
利益披露 Disclosure
Y. Liu, None.. I. C. Lubo Julio, None.. W. Lu, None.. A. G. Serrano, None.. J. R. Clemenceau, None.. A. Famiglietti, None.. K. Colbert, None.. Y. Dai, None.. Y. Liu, None.. J. Wang, None.. J. L. Davis, None.. T. Hwang, None.. L. Wang, None.

在会议检索中打开